Kirkland & Ellis is advising KKR on the financing for its investment in Immedica Pharma, a Swedish pharmaceutical company focused on medicines for rare diseases and specialty care. Immedica Pharma’s existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.
The debt facilities will, among other things, be used for acquisition proceeds as well as the ongoing capital expenditure and working capital requirements of the group.
The Kirkland team consisted of debt finance partners Ian Barratt and Jia Meng, with the support of debt finance associates Deena Smith and Ashley Bannister.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
